Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.54 |
| ▸ | BTK | Q06187 | 2/20 | 0.52 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | IL1B | P01584 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.49 |
| ▸ | GRAMD1A | Q96CP6 | 3/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24819464 | 1.00 | CRBN (0.54) | CRBNDDB1BTKIKZF3TNF | |
| SCHEMBL30732167 | 0.97 | CRBN (0.54) | CRBNDDB1BTKIKZF3TNF | |
| SCHEMBL26925221 | 0.97 | CRBN (0.54) | CRBNDDB1BTKIKZF3TNF | |
| SCHEMBL31129396 | 0.95 | CRBN (0.53) | CRBNDDB1BTKIKZF3TNF | |
| SCHEMBL31129461 | 0.91 | CRBN (0.56) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL20294709 | 0.91 | CRBN (0.59) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL29259959 | 0.90 | CRBN (0.55) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL30135751 | 0.90 | CRBN (0.55) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL30731968 | 0.89 | CRBN (0.54) | CRBNDDB1BTKIKZF3TNF | |
| SCHEMBL26924761 | 0.89 | CRBN (0.54) | CRBNDDB1BTKIKZF3TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561999-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| EP-4562007-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| US-20240317711-A1 | AURKA SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA INC. (KR) | 2024-09-26 | — | — | US | disclosed |
| WO-2024026081-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026083-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317711-A1 | AURKA SELECTIVE DEGRADATION INDUCING COMPOUND | STUB1, AURKA, XIAP | CRBN 757/4885DDB1 377/4885BTK 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.